deferoxamine has been researched along with Opportunistic Infections in 8 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Excerpt | Relevance | Reference |
---|---|---|
"Deferoxamine has been extensively used as chelation therapy in iron-overloaded states." | 2.38 | Novel uses of deferoxamine. ( Weinberg, K, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (37.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kubota, N | 2 |
Miyazawa, K | 2 |
Shoji, N | 2 |
Sumi, M | 2 |
Nakajima, A | 2 |
Kimura, Y | 2 |
Oshiro, H | 2 |
Ebihara, Y | 2 |
Ohyashiki, K | 2 |
Rahav, G | 1 |
Volach, V | 1 |
Shapiro, M | 1 |
Rund, D | 1 |
Rachmilewitz, EA | 1 |
Goldfarb, A | 1 |
Keijzer, A | 1 |
van der Valk, P | 1 |
Ossenkoppele, GJ | 1 |
van de Loosdrecht, AA | 1 |
Weinberg, K | 1 |
Sane, A | 1 |
Manzi, S | 1 |
Perfect, J | 1 |
Herzberg, AJ | 1 |
Moore, JO | 1 |
Fenves, A | 1 |
Windus, D | 1 |
Windus, DW | 1 |
Stokes, TJ | 1 |
Julian, BA | 1 |
Fenves, AZ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for deferoxamine and Opportunistic Infections
Article | Year |
---|---|
Novel uses of deferoxamine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Division; Deferoxamine | 1990 |
7 other studies available for deferoxamine and Opportunistic Infections
Article | Year |
---|---|
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Deferoxamine; Fatal Outcome; Humans; Male; | 2003 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr | 2003 |
Severe infections in thalassaemic patients: prevalence and predisposing factors.
Topics: Adolescent; Adult; Bacterial Infections; beta-Thalassemia; Child; Deferoxamine; Female; Ferritins; H | 2006 |
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Antibodies, Monoclonal; Apoptosis; Combined Modality Ther | 2006 |
Deferoxamine treatment as a risk factor for zygomycete infection.
Topics: Aged; Deferoxamine; Humans; Male; Mucormycosis; Opportunistic Infections; Rhizopus; Risk Factors | 1989 |
Uncertainty in clinical decisions.
Topics: Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Opportunistic Infections | 1988 |
Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.
Topics: Adult; Aged; Aluminum; Deferoxamine; Encephalitis; Female; Hemosiderosis; Humans; Male; Middle Aged; | 1987 |